Glucose-dependent insulinotropicpolypeptide agonist Glucose-dependent insulinotropic polypeptide, commonly known as GIP, is a vital intestinal hormone with a broad range of physiological actions, primarily focused on regulating postprandial metabolism. This 42-amino acid peptide is secreted by enteroendocrine K-cells in the upper small intestine in response to the ingestion of nutrients, particularly glucose and fats. GIP plays a crucial role in the incretin system, working alongside glucagon-like peptide-1 (GLP-1) to enhance insulin secretion and manage blood glucose levels.2025年2月6日—The numerous beneficial effects of GIPR signal modification render thepeptidean interesting candidate for the development of pharmacotherapies ... Understanding GIP's function is essential for comprehending nutrient absorption, glucose homeostasis, and its implications in metabolic diseases.
Upon the consumption of food, GIP is released into the bloodstream, where it acts on various tissues.作者：C Ji·2016·被引用次数：75—The incretin family contains the peptide glucose-dependent insulinotropic polypeptide (GIP) (Baggio and Drucker, 2007).GIP is a 42-amino-acid incretin hormonewhich activates pancreatic islets to enhance insulin secretion and to help reduce hyperglycemia, similar to the sister incretin glucagon ... Its most prominent effect is its potent stimulation of glucose-induced insulin secretion from pancreatic beta-cells.作者：Y Seino·2013·被引用次数：328—We review recent findings on theextrapancreatic effects of GIP and GLP-1on the heart, brain, kidney, eye and nerves, as well as in the liver, fat and several ... This action is glucose-dependent, meaning that GIP's ability to boost insulin release is significantly amplified when blood glucose levels are elevated.The Role of GIP in the Regulation of GLP-1 Satiety and Nausea | Diabetes This mechanism ensures that insulin is released precisely when it is needed most, to help clear glucose from the bloodstream and prevent hyperglycemia. Beyond insulin, GIP also influences glucagon secretion, generally suppressing it in the presence of high glucose but potentially stimulating it under fasting conditions.
GIP is often discussed in conjunction with GLP-1, as both are considered the major incretin hormones作者：IR Jones·1989·被引用次数：25—GIP is insulinotropic in the fasting statein patients with untreated type 2 diabetes mellitus and may stimulate the fi-cell continuously .... While both peptides are secreted after a meal and stimulate insulin release, they have distinct characteristics and physiological effects.Glucose-dependent insulinotropic polypeptide and ... GIP is released from K-cells in the duodenum and jejunum, whereas GLP-1 is secreted by L-cells in the ileum and colon. GIP's primary role is to enhance insulin secretion and promote glucose uptake, while GLP-1 also contributes to satiety, slows gastric emptying, and inhibits glucagon secretion. Research into the combined effects of GIP and GLP-1 is a significant area of study, exploring their synergistic actions in metabolic regulation and their potential as therapeutic targets.
While the pancreas is a primary target for GIP, its influence extends beyond this organ, affecting various extrapancreatic tissues. Emerging research highlights GIP's roles in the heart, brain, kidneys, and adipose tissue. These effects can include influencing lipid metabolism, promoting cardiovascular health, and potentially impacting neuroprotection.Glucose-dependent insulinotropic polypeptide and ... The exploration of these broader functions is uncovering new dimensions to GIP's importance in overall health and well-being.
Dysregulation of GIP signaling has been implicated in various metabolic disorders, most notably type 2 diabetesThe effects of glucose-dependent insulinotropic polypeptide .... In individuals with type 2 diabetes, the response to GIP can be impaired, a phenomenon known as "incretin resistance." While GIP still stimulates insulin secretion, the magnitude of this response is often blunted compared to healthy individuals. This diminished effectiveness contributes to the hyperglycemia characteristic of the disease. Consequently, GIP and its receptor (GIPR) are targets for the development of novel therapeutic strategies aimed at improving glucose control and managing metabolic conditionsSeparate and Combined Gluco-Metabolic Effects of .... Research into GIP agonists and modulators holds promise for future treatments.
Join the newsletter to receive news, updates, new products and freebies in your inbox.